ABUS Relative Valuation
ABUS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ABUS is overvalued; if below, it's undervalued.
Historical Valuation
Arbutus Biopharma Corp (ABUS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.39. The fair price of Arbutus Biopharma Corp (ABUS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：4.41
Fair
-28.35
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Arbutus Biopharma Corp. (ABUS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.11. The thresholds are as follows: Strongly Undervalued below -13.07, Undervalued between -13.07 and -7.59, Fairly Valued between 3.36 and -7.59, Overvalued between 3.36 and 8.84, and Strongly Overvalued above 8.84. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
EV/EBIT
Arbutus Biopharma Corp. (ABUS) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is -4.67. The thresholds are as follows: Strongly Undervalued below -11.07, Undervalued between -11.07 and -7.87, Fairly Valued between -1.48 and -7.87, Overvalued between -1.48 and 1.72, and Strongly Overvalued above 1.72. The current Forward EV/EBIT of 0.00 falls within the Overvalued range.
605.84
PS
Arbutus Biopharma Corp. (ABUS) has a current PS of 605.84. The 5-year average PS is 79.32. The thresholds are as follows: Strongly Undervalued below -167.68, Undervalued between -167.68 and -44.18, Fairly Valued between 202.83 and -44.18, Overvalued between 202.83 and 326.33, and Strongly Overvalued above 326.33. The current Forward PS of 605.84 falls within the Strongly Overvalued range.
0.00
P/OCF
Arbutus Biopharma Corp. (ABUS) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.62. The thresholds are as follows: Strongly Undervalued below -9.20, Undervalued between -9.20 and -5.91, Fairly Valued between 0.67 and -5.91, Overvalued between 0.67 and 3.95, and Strongly Overvalued above 3.95. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Arbutus Biopharma Corp. (ABUS) has a current P/FCF of 0.00. The 5-year average P/FCF is -7.17. The thresholds are as follows: Strongly Undervalued below -57.41, Undervalued between -57.41 and -32.29, Fairly Valued between 17.96 and -32.29, Overvalued between 17.96 and 43.08, and Strongly Overvalued above 43.08. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Arbutus Biopharma Corp (ABUS) has a current Price-to-Book (P/B) ratio of 10.94. Compared to its 3-year average P/B ratio of 5.29 , the current P/B ratio is approximately 106.87% higher. Relative to its 5-year average P/B ratio of 1.76, the current P/B ratio is about 520.02% higher. Arbutus Biopharma Corp (ABUS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -14.10%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -14.09% , the current FCF yield is about -100.00% lower.
10.94
P/B
Median3y
5.29
Median5y
1.76
-5.32
FCF Yield
Median3y
-14.10
Median5y
-14.09
Competitors Valuation Multiple
The average P/S ratio for ABUS's competitors is 0.00, providing a benchmark for relative valuation. Arbutus Biopharma Corp Corp (ABUS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -60.49%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ABUS increased by 34.86% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -10.02 to -19.63.
The secondary factor is the Margin Expansion, contributed -0.61%to the performance.
Overall, the performance of ABUS in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Arbutus Biopharma Corp (ABUS) currently overvalued or undervalued?
What is Arbutus Biopharma Corp (ABUS) fair value?
How does ABUS's valuation metrics compare to the industry average?
What is the current P/B ratio for Arbutus Biopharma Corp (ABUS) as of Dec 05 2025?
What is the current FCF Yield for Arbutus Biopharma Corp (ABUS) as of Dec 05 2025?
What is the current Forward P/E ratio for Arbutus Biopharma Corp (ABUS) as of Dec 05 2025?